Founded in 2016, Eyestem operates in Health Tech industry. Initially aimed at combating conditions like age-related macular degeneration, the company has evolved to include diverse cell therapy soluti...
Funding stage:
Series B
Last funding:
10/08/2025
Total funding:
$16.40 Mn+
Revenue:
Investors
Employee count:
24
Last 90d
24
Last 90d
Web traffic:
1.33K
1.33K
Last 30d
Last 30d
Eyestem: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders25
Latest Filing Date17 Oct 2024- Funding Events34
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Eyestem
As of 18 October 2024, Eyestem's equity is held by 23 shareholders, with the top three being Jogin Bhairav Desai, Jacesa Investments, and Cytespace Research.
Jogin Bhairav Desai holds the largest stake in Eyestem at 20.5% as of 18 October 2024.
As of 18 October 2024, founders collectively hold 27.1% equity in Eyestem.
As of 18 October 2024, investors collectively hold 22.4% equity in Eyestem.
Eyestem's ESOP pool stands at 9.8% of total equity as of 18 October 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links